$9.88
-0.05 (-0.45%)
Open$9.78
Previous Close$9.93
Day High$10.11
Day Low$9.69
52W High$12.10
52W Low$4.52
Volume—
Avg Volume16.8K
Market Cap90.10M
P/E Ratio114.42
EPS$0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-56.8% upside
Current
$9.88
$9.88
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.80M | 24.35M | 25.83M |
| Net Income | -1,045,742 | -824,284 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | 2.13M | 1.77M | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.34 | 0.34 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |